BLRD Merit Review Research Career Scientist Award

BLRD 优异评审研究职业科学家奖

• 批准号: 10594022
• 负责人: Shyam S Mohapatra
• 金额: --
• 依托单位: JAMES A. HALEY VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2029-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10594022
• 关键词: 2019-nCoV; 3-Dimensional; Acceleration; Affect; American; Anti-Inflammatory Agents; Artificial Intelligence; Asthma; Award; Biological Assay; Biology; Biopsy; Birds; CCL20 gene; COVID-19; Cell Therapy; Cells; Clinical; Clinical Trials; Collaborations; Data; Development; Diagnostic; Disease; Education; Educational process of instructing; Elderly; Endowment; Extramural Activities; Florida; Formulation; Funding; Future; General Population; Goals; Health; Healthcare; Hospitals; Hypersensitivity; Image Enhancement; Immunocompetent; Immunology; In Vitro; Incidence; Individual; Industry Collaboration; Inflammation; Inflammatory; International; Investments; Lead; Legal patent; Liposomes; Malignant neoplasm of brain; Malignant neoplasm of lung; Medicine; Mesenchymal Stem Cells; Methods; Modeling; Mus; Nanofiber Scaffold; Nature; Nerve Regeneration; Nursing Faculty; Oligosaccharides; Oncolytic; Peptides; Phospholipids; Pneumonia; Property; Prophylactic treatment; Publications; Reporting; Research; Research Activity; Research Personnel; Research Support; Respiratory Syncytial Virus Infections; Respiratory syncytial virus; SARS-CoV-2 antiviral; Safety; Scientist; Seminal; Small Interfering RNA; System; Technology; Testing; Therapeutic; Translations; Traumatic Brain Injury; United States Department of Veterans Affairs; United States National Institutes of Health; Universities; Veterans; Viral; Viral Respiratory Tract Infection; Virus Diseases; Work; bench to bedside; career; chest computed tomography; clinical diagnosis; clinical diagnostics; clinical training; combinatorial; drug efficacy; efficacy testing; experience; graduate student; human disease; improved; in vivo; indexing; influenza infection; inhibitor; innovation; mouse model; nano; nanoformulation; nanomedicine; nanomicelles; nanoscale; nanosystems; nanotherapeutic; novel; novel diagnostics; novel therapeutics; novel virus; pandemic disease; particle; personalized cancer therapy; prevent; professor; prophylactic; respiratory infection virus; stem cell therapy; translational medicine

This proposal seeks to renew Research Career Scientist Award held by Dr. Shyam S Mohapatra, at the James A. Haley VA Hospital in Tampa, Florida since 2007. He is a Distinguished Health Professor and the Director of the Division of Translational Medicine- Center for Research and Education in Nanobioengineering at the VA-affiliated academic center- the University of South Florida. With ~235 publications, 40 patents, an h-index of 53 and an i-index of 161, he is recognized nationally and internationally for his contributions to the field of nanoscale biomedical diagnostics and therapeutics in relation to viral infections, traumatic brain injury (TBI) and cancers. He has received substantial extramural research support including awards from the NIH, DOA, ONR, Department of Veterans’ Affairs and Florida Department of Health. He is the recipient of several international/national awards and recognitions. Dr. Mohapatra has been a research investigator at the VA Hospital (Medicine) since 1996 and has been continuously funded with the Merit Review Award focused on respiratory syncytial virus (RSV) infection since 1999. Current and ongoing research activities to be supported by this RCS Award are as follows. Project #1. a) Develop new prophylactic, or therapeutic approaches involving broad antiviral and anti-inflammatory compounds formulated using novel nanoscale technologies, which are effective against COVID-19 and other respiratory viral infections. The currently proposed Merit Review project aims to develop a simple, smart and translatable nanoscale system that combines novel targets for antiviral- and replication and inflammation inhibitors. He currently leads two additional projects, as a multi-PI. This proposal aims to characterize novel virus-neutralizing particles that may serve as prophylaxis and/or therapy. b) Also, based on his recent experience in artificial intelligence (AI)-enhanced imaging, and preliminary data with COVID-19, he was funded by CSRD to examine the potential to clinically diagnose and prognose COVID 19 by AI-aided chest CT. Project #2. Investigate and test a novel targeted oncolytic viro-cell therapy (OVT) for lung cancer using the mesenchymal stem cell (MSCs) infected by RSV, which is harmless for immunocompetent individuals. Thus, it is planned to use a 3D multicell tumoroid and biopsy-derived cultures in vitro and mouse model of lung cancer in vivo to evaluate the safety and efficacy of OVT. The project to data has attracted industry collaboration, which might lead to clinical trials. Project #3. Investigate the potential of a novel combinatorial therapeutic approach in a mouse CCI model of moderate TBI that includes (i) a treatment to reduce inflammation (local and systemic) using a nano-formulated siRNA against a recently discovered target, CCL20, and (ii) a second treatment to promote neuroregeneration by MSC therapy. VA Impact: These highly innovative applications of nanomedicine approaches taken together are expected to lead to high-impact clinical diagnostics and therapies for Veterans and other Americans in need. Veterans have been proportionately affected by the pandemic, and are increasingly affected by the incidence of lung cancers and TBI compared to the general population. The development of these effective nanotherapeutics will greatly improve the quality of Veteran’s healthcare.

该提案旨在延续 Shyam S Mohapatra 博士持有的研究职业科学家奖， 自 2007 年起在佛罗里达州坦帕市的 James A. Haley VA 医院工作。他是一位杰出健康人士 研究中心教授兼转化医学部主任 退伍军人管理局附属学术中心——南方大学的纳米生物工程教育 佛罗里达州，拥有约 235 篇出版物、40 项专利、h 指数为 53、i 指数为 161，受到认可。 在国内和国际上表彰他在纳米级生物医学诊断领域的贡献 以及与病毒感染、创伤性脑损伤 (TBI) 和癌症相关的治疗方法。 获得了大量的校外研究支持，包括来自 NIH、DOA、ONR 的奖项， 他是退伍军人事务部和佛罗里达州卫生部的多项获奖者。 Mohapatra 博士曾担任以下机构的研究员。 自 1996 年以来一直在 VA 医院（内科）工作，并通过绩效审查持续获得资助 自 1999 年以来该奖项专注于呼吸道合胞病毒 (RSV) 感染。当前和正在进行中 RCS 奖支持的研究活动如下。 项目#1。a) 开发涉及广泛抗病毒药物的新预防或治疗方法 和使用新型纳米技术配制的抗炎化合物， 有效对抗 COVID-19 和其他呼吸道病毒感染 目前提出的优点 Review项目旨在开发一种简单、智能且可翻译的纳米级系统，该系统结合了 他目前领导两个抗病毒、复制和炎症抑制剂的新靶点。 其他项目，作为多 PI 该提案旨在表征新型病毒中和颗粒。 b) 另外，根据他最近在人工方面的经验 智能 (AI) 增强成像以及 COVID-19 的初步数据，他获得了 CSRD 的资助 研究通过 AI 辅助胸部 CT 进行临床诊断和预测 COVID 19 的潜力。 项目#2。研究并测试一种新型的肺部靶向溶瘤病毒细胞疗法（OVT）。 使用RSV感染的间充质干细胞（MSC）进行癌症治疗，RSV对人体无害 因此，计划使用 3D 多细胞肿瘤和活检来源的个体。 体外培养和体内肺癌小鼠模型以评估 OVT 的安全性和有效性。 该数据项目吸引了行业合作，这可能会导致临床试验。 项目#3。研究一种新型组合治疗方法的潜力。 中度 TBI 小鼠 CCI 模型，包括 (i) 减少炎症（局部和局部）的治疗 系统性）使用纳米配方的 siRNA 针对最近发现的靶标 CCL20，以及 (ii) 第二个治疗是通过间充质干细胞疗法促进神经再生。 VA 影响：纳米医学方法的这些高度创新的应用 预计将为退伍军人和老年人带来高影响力的临床诊断和治疗 其他需要帮助的美国人也受到了这一流行病的相应影响，并且正在受到影响。 与一般人群相比，肺癌和 TBI 发病率的影响越来越大。 这些有效纳米疗法的开发将大大提高退伍军人的质量 卫生保健。